GS Labs Countersues Blue Cross Blue Shield of Minnesota: Federal Court Filing Accuses Insurer of Antitrust Violations, Conspiring With Cartel of BCBS Affiliates, Violating CARES ACT, False Advertising and Consumer Fraud
Retrieved on:
Wednesday, June 29, 2022
Insurance, Blue Cross, BCBS, Board of directors, Patient, Implementation history of the Affordable Care Act, Fraud, COVID, CARES Act, COVID-19, Greed, District court, Public health, Association, COVID-19 testing, District, GS, Wang, Blue Cross Blue Shield Association, Blues, Bone, AHIP, Health, Hospital Insurance and Diagnostic Services Act, Blue, Board, Deception, Pharmaceutical industry, Health insurance
MINNEAPOLIS, June 29, 2022 /PRNewswire/ -- GS Labs, a leading provider of COVID-19 rapid tests in Minnesota and across the nation has filed new counterclaims in the company's ongoing legal battle against multi-billion-dollar insurance giant Blue Cross Blue Shield of Minnesota.
Key Points:
- The June 29th filing in U.S. District Court for the District of Minnesota flatly denies all prior allegations made by BCBS of Minnesota against GS Labs.
- However, BCBS of Minnesota's conduct raises new concerns that it and its sisters Blues continue to engage in anticompetitive behavior.
- "The countersuit demonstrates Blue Cross and Blue Shield's greed and deception amidst a massive public health emergency," said Wang.
- Many communities directly requested assistance from GS Labs, due to a lack of testing resources.